ArticleBrain and behavior2025
Association Between Peripheral Inflammation Biomarkers and Clinical Phenotypes in Patients With Medication Overuse Headache: A Cross-sectional Study.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe role of peripheral inflammation in medication overuse headache (MOH) remains inadequately understood. This study aimed to investigate biomarkers of peripheral inflammation in MOH patients and examine their relationship with clinical features.
methodsThe study comprised 128 MOH patients and 132 age- and sex-matched controls, including 60 episodic migraine patients and 72 healthy controls (HC). Inflammatory markers derived from blood cell counts were assessed in all participants. Clinical features, including headache days and intensity per month and days per month with acute medication, were documented.
resultsIn MOH patients, the aggregate index of systemic inflammation (AISI) was higher compared to healthy controls, and both MOH and episodic migraine patients had elevated systemic inflammation response index (SIRI) levels. AISI and SIRI were positively correlated with the days per month with acute medication, while systemic inflammation index (SII), SIRI, AISI, and other inflammatory markers correlated with headache duration. AISI proved more effective than SII and SIRI in diagnosing MOH. Furthermore, elevated SII and AISI levels were significantly associated with MOH after adjusting for age and sex.
conclusionThe study found significant correlations between SII, SIRI, and AISI and clinical phenotypes in MOH. Elevated SII and AISI levels were significantly linked to MOH, implying that these peripheral inflammation biomarkers could enhance the understanding of MOH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.